Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2016-07-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
关于本次重大资产重组不存在内幕交易行为的说明
Regulatory Filings Classification · 95% confidence The document is a statement from SanNuo Bio-Sensor Co., Ltd. regarding the absence of insider trading related to a major asset restructuring. It references regulatory guidelines from the China Securities Regulatory Commission concerning major asset restructurings and insider trading checks. The content focuses on self-examination and declarations by related parties about stock transactions during the review period. There are no financial statements, earnings data, or management discussion of financial results. The document is a compliance and regulatory disclosure related to a major asset restructuring transaction, specifically addressing insider trading concerns. It is not an audit report, annual report, or earnings release. It is not a proxy or voting result announcement. It is a regulatory compliance disclosure about insider trading in connection with a major asset restructuring. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-07-14 Chinese
董事会关于本次重组履行法定程序的完备性、合规性及提交法律文件的有效性说明
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from the board of directors of 三诺生物传感股份有限公司 regarding the completeness, compliance, and validity of legal documents submitted for a major asset restructuring transaction. It references multiple prior announcements about the progress of the major asset restructuring, including suspension of trading, due diligence, audits, and regulatory compliance with the Shenzhen Stock Exchange and China Securities Regulatory Commission rules. The document does not contain financial statements or detailed financial data but rather focuses on procedural and legal compliance related to the restructuring process. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement. The content fits best as a Regulatory Filing (RNS) because it is a regulatory compliance announcement related to a major asset restructuring, providing legal and procedural assurances without substantive financial data or report content.
2016-07-14 Chinese
关于重大资产重组的一般风险提示公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "General Risk Warning Announcement Regarding Major Asset Restructuring" and discusses the company's plan for a significant asset reorganization involving issuance of shares to purchase assets. It references prior announcements and approvals related to the asset purchase plan. The document is an announcement about the risks associated with the major asset restructuring and the regulatory environment, rather than the detailed asset purchase plan itself or the full transaction documents. It does not contain financial statements or detailed financial data but serves as a risk disclosure and update on the restructuring process. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings and share issuance plans.
2016-07-14 Chinese
第二届董事会第三十六次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of a company regarding a significant transaction involving the issuance of shares to purchase assets, specifically the acquisition of shares in other companies and related financing and lock-up arrangements. It includes detailed voting results, pricing, payment methods, lock-up commitments, and compliance with regulatory requirements. The content is focused on capital structure changes and financing activities related to the issuance of shares for asset acquisition. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a simple announcement of voting results but a detailed board resolution on a capital transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2016-07-14 Chinese
创业板上市公司重大资产重组方案首次披露对照表
M&A Activity Classification · 95% confidence The document is a detailed disclosure related to a major asset restructuring plan of a listed company (三诺生物) on the Shenzhen Stock Exchange (证券代码 300298.SZ). It includes extensive information about the restructuring proposal, related approvals, financial reports, audit opinions, legal opinions, independent financial advisor reports, risk disclosures, and compliance with regulatory requirements under the Chinese securities regulatory framework (e.g., references to 《重组办法》, 中国证监会). The document contains comprehensive financial and legal details, including audited financial statements, valuation reports, and risk factors, which are typical components of a major asset restructuring report. It is not a brief announcement or a simple notice but a full disclosure document with substantive financial and legal content. This matches the characteristics of a "Major Asset Restructuring Report" which is a type of detailed regulatory filing related to mergers and acquisitions and restructuring activities. Given the filing definitions, the closest and most appropriate category is "M&A Activity (Code: TAR)" which covers announcements and documents related to merger proposals or takeover bids, including major asset restructuring plans. The document is too detailed and substantive to be a mere announcement (RPA) or a general regulatory filing (RNS). Therefore, the classification is TAR with high confidence.
2016-07-14 Chinese
重组预案独立财务顾问核查意见表
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion form related to a major asset restructuring plan involving issuance of shares to purchase assets. It references compliance with the "Reorganization Measures" and "26th Guideline" and includes extensive due diligence on the transaction parties, asset valuation, legal and financial compliance, and regulatory approvals. The content is focused on a major asset restructuring transaction, including issuance of shares for asset purchase, and the document is comprehensive and substantive, not merely an announcement or certification. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report concerning a major asset restructuring, including financial and legal due diligence, but is not a full annual report or interim report. Therefore, the appropriate classification is AR with high confidence. FY 2015
2016-07-14 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.